Table 1:
Baseline Characteristics
| IL-2RA (n=13,864) | ATG (n=15,756) | AZM (n=3,438) | No induction (n=14,200) | |
|---|---|---|---|---|
| Recipient factors | ||||
| Age (Years) | 49.0 (38.0, 58.0) | 49.0 (39.0, 58.0) | 50.0 (40.0, 59.0) | 48.0 (37.0, 57.0) |
| Female sex | 37.4% | 43.2% | 40.1% | 38.6% |
| BMI (kg/m2) | 26.3 (23.1, 30.2) | 27.0 (23.6, 31.1) | 27.4 (23.8, 31.6) | 26.2 (23.0, 30.2) |
| Race/Ethnicity | ||||
| White | 47.1% | 43.7% | 48.7% | 47.3% |
| African American | 24.5% | 32.8% | 31.0% | 28.0% |
| Hispanic/Latino | 18.5% | 15.2% | 14.6% | 17.0% |
| Other/multi-racial | 9.9% | 8.3% | 5.7% | 7.7% |
| Attended college | 37.4% | 37.4% | 43.0% | 34.4% |
| Preemptive transplant | 14.3% | 13.8% | 19.7% | 17.7% |
| Years on dialysis | 2.5 (1.0, 4.6) | 3.0 (1.2, 5.0) | 2.6 (0.5, 4.9) | 2.3 (0.5, 4.3) |
| Cause of ESRD | ||||
| GN | 26.3% | 24.5% | 22.8% | 24.6% |
| DM | 20.9% | 21.5% | 23.3% | 19.3% |
| HTN | 18.8% | 22.1% | 23.5% | 21.0% |
| Others | 34.0% | 31.8% | 30.4% | 35.1% |
| HCV(+) | 4.8% | 5.0% | 3.3% | 5.3% |
| Peak PRA | 0.0 (0.0, 8.0) | 2.0 (0.0, 22.0) | 3.0 (0.0, 19.0) | 0.0 (0.0, 10.0) |
| Zero HLA mismatch | 11.6% | 8.3% | 8.3% | 12.6% |
| ABO incompatible | 0.3% | 0.6% | 0.6% | 0.4% |
| Cold ischemia time (Hr) | 13.0 (3.0, 20.9) | 14.0 (6.0, 21.0) | 15.0 (2.0, 22.1) | 14.0 (2.6, 21.0) |
| Maintenance Immunosuppression | ||||
| Steroid maintenance | 89.6% | 68.5% | 22.7% | 87.8% |
| Cyclosporine | 29.7% | 12.9% | 3.3% | 30.1% |
| Tacrolimus | 64.3% | 82.2% | 92.0% | 64.6% |
| MMF | 88.5% | 88.9% | 83.4% | 80.8% |
| mTOR | 9.1% | 8.7% | 1.5% | 9.5% |
| Azathioprine | 1.8% | 1.6% | 0.2% | 2.2% |
| Donor factors | ||||
| Age (Years) | 39.0 (26.0, 50.0) | 41.0 (26.0, 51.0) | 42.0 (29.0, 52.0) | 39.0 (26.0, 49.0) |
| Female sex | 46.7% | 46.0% | 47.8% | 46.0% |
| Race/Ethnicity | ||||
| White | 65.5% | 67.8% | 68.3% | 66.6% |
| African American | 12.3% | 14.6% | 15.5% | 13.5% |
| Hispanic/Latino | 17.1% | 13.7% | 13.0% | 15.9% |
| Other/multi-racial | 5.2% | 3.9% | 3.2% | 4.0% |
| Deceased donor | 64.6% | 72.8% | 63.2% | 63.9% |
| Among deceased donors: | ||||
| Serum Creatinine (mg/dL) | 0.9 (0.7, 1.2) | 1.0 (0.7, 1.3) | 1.0 (0.7, 1.3) | 1.0 (0.7, 1.2) |
| DCD | 3.8% | 7.8% | 9.0% | 3.5% |
| ECD | 9.9% | 13.2% | 14.6% | 9.9% |
AZM: alemtuzumab, ATG: anti-thymocyte globulin, DM: Diabetes mellitus, DCD: Donation after cardiac death, ECD: expanded criteria donor, ESRD: end stage renal disease, GN: glomerulonephritis, HCV: hepatitis C virus, HTN: Hypertension, IL-2RA: IL-2 receptor antagonist, mTOR: mammalian target of rapamycin, MMF: mycophenolate mofetil, PRA: panel reactive assay